Sars-CoV2: Clinical Trials

10 trials for Sars-CoV2, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 unknown. 10 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 310Unknown 10
Phase 24Unknown 4

Follow Sars-CoV2: new trials by email Literature Review of Sars-CoV2 trials Research Report on Sars-CoV2

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19
Peginterferon Lambda-1A, Placebo - Sars-CoV2, Covid19
Phase 3UnknownUniversity Health Network, Toronto7632021-08-272022-04-05
Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19
Ribavirin Capsules, Favipiravir - SARS-CoV2, COVID-19
Phase 2 / Phase 3UnknownThe Scientific and Technological Research Council of Turkey1002021-04-012021-04-02
Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)
Hydroxychloroquine Only Product in Oral Dose Form - Sars-CoV2, Coronavirus Infection
Phase 2 / Phase 3UnknownUniversity of Malaga19302020-09-012020-09-29
Clinical Trial to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers
RUTI® vaccine, Placebo - Covid-19, Sars-CoV2
Phase 3UnknownFundació Institut Germans Trias i Pujol3152020-07-302020-07-29
Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers
BCG vaccine, Placebo - BCG, COVID-19
Phase 3UnknownHospital Universitario Dr. Jose E. Gonzalez9082020-07-212020-11-13
CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms
Cannabidiol, PLACEBO - SARS-CoV2
Phase 2 / Phase 3UnknownUniversity of Sao Paulo1002020-07-062021-09-28
Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19
SARS-CoV-2 convalescent plasma treatment, Standard care - Sars-CoV2, Covid-19
Phase 2 / Phase 3UnknownFundación Santa Fe de Bogota2362020-07-012020-06-11
Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19
Favipiravir (3200 mg + 1200 mg), Favipiravir (3600 mg + 1600 mg), Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine - Sars-CoV2, COVID-19
Phase 3UnknownMinistry of Health, Turkey10082020-05-082021-02-01
A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers
Hydroxychloroquine, Hydroxychloroquine (placebo), Zinc - Sars-CoV2, COVID19
Phase 3UnknownMilitary Hospital of Tunis6602020-05-042020-05-06
Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)
Hydroxychloroquine, Placebo - COVID-19, Corona Virus Infection
Phase 3UnknownLouisiana State University Health Sciences Center in New Orleans17002020-04-272020-09-02

Narrower conditions

COVID-19 (9)  ·  Coronavirus Infections (3)

Broader conditions

Coronaviridae Infections (9)  ·  Infections (9)  ·  Lung Diseases (9)  ·  Nidovirales Infections (9)  ·  Pneumonia (9)  ·  Pneumonia, Viral (9)  ·  RNA Virus Infections (9)  ·  Respiratory Tract Diseases (9)  ·  Respiratory Tract Infections (9)  ·  Virus Diseases (9)  ·  Coronavirus Infections (6)

Interventions

Hydroxychloroquine (3)  ·  favipiravir (2)  ·  Azithromycin (1)  ·  BCG Vaccine (1)  ·  COVID-19 Serotherapy (1)  ·  Cannabidiol (1)  ·  Dosage Forms (1)  ·  Ribavirin (1)  ·  Standard of Care (1)  ·  Zinc (1)  ·  peginterferon lambda-1a (1)

Sponsors

Fundació Institut Germans Trias i Pujol (1)  ·  Fundación Santa Fe de Bogota (1)  ·  Hospital Universitario Dr. Jose E. Gonzalez (1)  ·  Louisiana State University Health Sciences Center in New Orleans (1)  ·  Military Hospital of Tunis (1)  ·  Ministry of Health, Turkey (1)  ·  The Scientific and Technological Research Council of Turkey (1)  ·  University Health Network, Toronto (1)  ·  University of Malaga (1)  ·  University of Sao Paulo (1)

Countries

Turkey (Türkiye) (2)  ·  Brazil (1)  ·  Canada (1)  ·  Colombia (1)  ·  Mexico (1)  ·  Spain (1)  ·  Tunisia (1)  ·  United States (1)

Top investigators

Faida Ajili, MD (1)  ·  Jordan Feld, MD (1)  ·  Juan C Morilla-Herrera, PhD (1)  ·  Nejla Mrabet, PhD (1)  ·  Pere-Joan Cardona, MD, PhD (1)

Results publications

PMID 34619044